AAL

Struggling Biopharma Stock Blasts Higher After Upbeat Data

NKTX hit a record low just last session

Deputy Editor
Apr 25, 2022 at 10:35 AM
facebook X logo linkedin


Biopharmaceutical stock Nkarta Inc (NASDAQ:NKTX) is skyrocketing today, up 91.4% at $14.87 at last check, after the company announced positive preliminary data for two of its experimental cell therapy treatments. Specifically, NKX101 and NKX019 both showed promise in treating different blood disorders, with no reports of side effects. 

Fresh off a five week losing streak, NKTX has had a rough time on the charts this year. Last session, the stock hit a record low of $7.55. Still down 55.2% year-over-year, Nkarta stock is now hovering just below its year-to-date breakeven levels. Today's soaring price action has the equity breaking above several moving averages, however, including the 120-day trendline, which rejected the stock earlier this month. 

A stint of short covering could send the security higher, too. Short interest represents 6.3% of the stock's available float, or over eight days' worth of pent-up buying power. Plus, NKTX's 14-day Relative Strength Index (RSI) of 20 sits firmly in "oversold" territory. This means the stock could be due for a short-term bounce. 

Nkarta stock's typically quiet options pits were roaring with activity this morning, before trading was halted, with options volume running at 47 times the typical daily volume. The security saw 11,000 calls and 6,144 puts cross the tape, with the May 20 put and 22.50 call seeing the most movement. 

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.